Immunovant Inc Earnings

Immunovant Inc’s revenue fell -89.33% since last year same period to $0.16Mn in the Q1 2025. On a quarterly growth basis, Immunovant Inc has generated +Inf% jump in its revenue since last 3-months.

Immunovant Inc’s net profit fell -41.33% since last year same period to $-106.45Mn in the Q1 2025. On a quarterly growth basis, Immunovant Inc has generated 4.21% jump in its net profits since last 3-months.

Immunovant Inc’s net profit margin fell -1224.98% since last year same period to -66530.63% in the Q1 2025. On a quarterly growth basis, Immunovant Inc has generated NaN% jump in its net profit margins since last 3-months.

Immunovant Inc’s earning per share (EPS) estimates for the current quarter stand at -0.74 - a -4.81% fall from last quarter’s estimates.

Immunovant Inc’s earning per share (EPS) estimates for the current year stand at -0.74.

Immunovant Inc’s earning per share (EPS) jumped 100% since last year same period to 0 in the Q3 2025. This indicates that the Immunovant Inc has generated 100% annual rate of jump in its earning per share (EPS) in the last 4 quarters.